Trials / Recruiting
RecruitingNCT06966141
A Real World Study of Sacituzumab Govitecan
A Real World Study: Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 Negative Breast Cancer Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 negative Breast Cancer Patients
Conditions
Timeline
- Start date
- 2024-08-12
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
- First posted
- 2025-05-11
- Last updated
- 2025-05-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06966141. Inclusion in this directory is not an endorsement.